Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal

Nature

Volumn 464, Issue 7287, 2010, Pages 436-440

  Sotillo, Rocio ^a   Schvartzman, Juan Manuel ^a   Socci, Nicholas D ^a   Benezra, Robert ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; ENZYME; PROTEIN KRAS; PROTEIN MAD2; UNCLASSIFIED DRUG;

CHROMOSOME; DISEASE TREATMENT; GENE; RESPIRATORY DISEASE; RODENT; TUMOR;

ANEUPLOIDY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CHROMOSOMAL INSTABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE INACTIVATION; GENE INDUCTION; GENE OVEREXPRESSION; LUNG TUMOR; MITOSIS; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR RECURRENCE;

ANEUPLOIDY; ANIMALS; CELL CYCLE PROTEINS; CHROMOSOMAL INSTABILITY; LUNG NEOPLASMS; MICE; MICE, TRANSGENIC; NEOPLASM RECURRENCE, LOCAL; ONCOGENES; PROTO-ONCOGENE PROTEINS P21(RAS);

MUS;

EID: 77949773695     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature08803     Document Type: Article

References (28)

1. Weinstein, I. B. & Joe, A. K. Mechanisms of disease: oncogene addiction\a rationale for molecular targeting in cancer therapy. Naure. Clin. Pract. Oncol. 3, 448-457 (2006).
2. Hernando, E. et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 430, 797-802 (2004).
3. Sotillo, R. et al. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 11, 9-23 (2007).
4. Schvartzman, J. M., Sotillo, R. & Benezra, R. Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nature Rev. Cancer 10, 102-115 (2010).
5. Ricke, R. M., van Ree, J. H. & van Deursen, J. M. Whole chromosome instability and cancer: a complex relationship. Trends Genet. 24, 457-466 (2008).
6. Chang, S., Khoo, C. & DePinho, R. A. Modeling chromosomal instability and epithelial carcinogenesis in the telomerase-deficient mouse. Semin. Cancer Biol. 11, 227-239 (2001).
7. Tichelaar, J. W., Lu, W. & Whitsett, J. A. Conditional expression of fibroblast growth factor-7 in the developing and mature lung. J. Biol. Chem. 275, 11858-11864 (2000).
8. Fisher, G. H. et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15, 3249-3262 (2001).
9. Chin, L. et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400, 468-472 (1999).
10. Felsher, D. W. & Bishop, J. M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell 4, 199-207 (1999).
11. Giuriato, S. & Felsher, D. W. How cancers escape their oncogene habit. Cell Cycle 2, 329-332 (2003).
12. Boxer, R. B., Jang, J. W., Sintasath, L. & Chodosh, L. A. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell 6, 577-586 (2004).
13. Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (New York, N. Y.) 293, 876-880 (2001).
14. Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792 (2005).
15. Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005).
16. Politi, K. et al. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. 20, 1496-1510 (2006).
17. Baker, D. J., Chen, J. & van Deursen, J. M. The mitotic checkpoint in cancer and aging: what have mice taught us? Curr. Opin. Cell Biol. 17, 583-589 (2005).
18. Pérez de Castro, I., de Cárcer, G. & Malumbres, M. A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy. Carcinogenesis 28, 899-912 (2007).
19. Dobles, M., Liberal, V., Scott, M. L., Benezra, R. & Sorger, P. K. Chromosome missegregation and apoptosis in mice lacking the mitotic checkpoint protein Mad2. Cell 101, 635-645 (2000).
20. Li, M., York, J. P. & Zhang, P. Loss of Cdc20 causes a securin-dependent metaphase arrest in two-cell mouse embryos. Mol. Cell. Biol. 27, 3481-3488 (2007).
21. Kwon, M. et al. Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes. Genes Dev. 22, 2189-2203 (2008).
22. Weaver, B. A., Silk, A. D., Montagna, C., Verdier-Pinard, P. & Cleveland, D. W. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 11, 25-36 (2007).
23. Rao, C. V. et al. Colonic tumorigenesis in BubR11/2ApcMin/1 compound mutant mice is linked to premature separation of sister chromatids and enhanced genomic instability. Proc. Natl Acad. Sci. USA 102, 4365-4370 (2005).
24. Jeganathan, K., Malureanu, L., Baker, D. J., Abraham, S. C. & van Deursen, J. M. Bub1 mediates cell death in response to chromosome missegregation and acts to suppress spontaneous tumorigenesis. J. Cell Biol. 179, 255-267 (2007).
25. Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037 (2001).
26. Cortes, J. & O'Dwyer, M. E. Clonal evolution in chronic myelogenous leukemia. Hematol. Oncol. Clin. North Am. 18, 671-684 (2004).
27. Hochhaus, A. et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16, 2190-2196 (2002).
28. O'Dwyer, M. E. et al. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 100, 1628-1633 (2002).